Multiple Sclerosis New Zealand is aware that your DHB has been presented with a Business Case to make autologous haematopoietic stem cell transplants (aHSCT) available in your DHB to patients with Multiple Sclerosis. Multiple Sclerosis New Zealand requests a copy of this Business Case along with further information including any analysis of the business case correspondence etc regarding your decisions on this application.

Tags aHSCTAutologous haematopoietic stem cell transplantsMultiple SclerosisStem cell transplants

More informationDownload pdf (100KB)